Characteristics | Â | Number | Percent |
---|---|---|---|
Age, mean (SD) | Â | 52.3 (12.7) | Â |
Gender | Male | 36 | 57.1% |
 | Female | 27 | 42.9% |
ECOG PS | 0 | 44 | 69.8% |
 | 1 ~ 2 | 19 | 30.2% |
BMI, mean (SD) | Â | 21.3 (2.94) | Â |
Tumor location | GEJ | 15 | 23.8% |
 | Stomach | 48 | 76.2% |
Tumor differentiation | Well-moderate | 6 | 9.5% |
 | Poor | 51 | 81.0% |
 | Unknown | 6 | 9.5% |
Number of organs with metastasis, median (IQR) |  | 2 (1–2) |  |
Lines of anti-PD-1 therapy | First line | 36 | 57.1% |
 | Second line or later | 27 | 42.9% |
Cycles of anti-PD-1 therapy, median (IQR) |  | 5 (4–8) |  |
HER2 status | Positive | 12 | 19.0% |
 | Negative | 51 | 81.0% |
PD-L1 expression | CPS ≥ 1 | 50 | 79.4% |
 | CPS < 1 | 13 | 20.6% |
MMR status | pMMR | 53 | 84.1% |
 | dMMR | 4 | 6.3% |
 | Unknown | 6 | 9.5% |
EBV status | Positive | 4 | 6.3% |
 | Negative | 51 | 81.0% |
 | Unknown | 8 | 12.7% |
Disease response (RECIST 1.1) | CR | 8 | 12.7% |
 | PR | 23 | 36.5% |
 | SD | 18 | 28.6% |
 | PD | 14 | 22.2% |
NLR, mean (SD) | Â | 3.56 (2.71) | Â |
LMR, mean (SD) | Â | 3.62 (3.96) | Â |